Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceutical Group Co., Ltd. is the only pharmaceutical listed company in China that has a leading position in pharmaceutical products and distribution markets. The company's R&D is based on innovation as its long-term adherence to, and is committed to providing safe and effective therapeutic drugs for major diseases and chronic diseases. In 2012, R&D investment accounted for 4.72% of the company's pharmaceutical business sales revenue. The company has established a research and development system for the branch of the Group General Academy with the Central Research Institute as its technical core, with 1 national-level enterprise technology center and 10 provincial and municipal enterprise technology centers, and has been selected for more than ten major national science and technology projects of "major new drug creation". The company adopts an open research model, established a strategic alliance for innovative drug research and development with the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, established joint laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, etc., and cooperated with Japan's Mitsubishi Tanabe Pharmaceutical Co., Ltd. and Shanghai Fudan Zhangjiang Biomedicine to carry out innovative drug research and development; at the same time, it also began to enter the field of therapeutic antibodies through project introduction, cooperative development and other methods. Shanghai pharmaceutical manufacturing covers the fields of chemical and biological medicine, modern Chinese medicine and health products, medical devices, etc. The products focus on five major therapeutic areas: cardiovascular and cerebrovascular, systemic anti-infection, digestive system and immunometabolism, neuropsychiatric, and anti-tumor. It produces more than 20 dosage forms such as tablets, capsules, powder injections (including lyophilized), small-volume injections, eye drops, aerosols, gels, etc., and has over 100 million products. The company's Xinyi, Leishi, Longhu, Qingchunbao, Hu Qingyutang, Cangsong, Guofeng, Shenxiang and other brands are well-known trademarks in China. The company's pharmaceutical production strictly implements China's new version of GMP requirements, and multiple raw materials or preparations have passed the quality certification of WHO, FDA, the EU and other developed countries. Shanghai Pharmaceutical's distribution network radiates across the country with the three key areas of East China, North China and South China, with the most economically developed in China, and ranks second in the country in terms of business scale. The company's distribution business is mainly hospital pure sales, and it cooperates with more than 40 multinational pharmaceutical companies around the world. The company's new businesses such as vaccines, high-end consumables, DTP (direct delivery of high-value drugs) and SPD (pharmaceutical flow management technology) are leading in China. The company's distribution services are gradually moving towards modern hospital service solutions with supply chain extension services and clinical support services as the core, providing hospital customers with terminal solutions, special logistics and information services. Shanghai Pharmaceutical Retail has many well-known brands such as Fahrenheit, Lei Yunshang, Yu Tiancheng, Life Insurance, Leimon, Keyuan Xinhai Pharmacy, etc., covering 12 provinces, municipalities and autonomous regions across the country, with a total of 1,792 stores. In 2012, the company's pharmaceutical retail sales scale ranked among the top five in the national pharmaceutical retail industry, and Shanghai Fahrenheit Pharmacy is the company with the largest number of pharmacies in East China. Shanghai Pharmaceutical's retail business includes chain pharmacies, co-organized pharmacies, DTP pharmacies and other business formats, and actively develops e-commerce to achieve online sales. Shanghai Pharmaceutical advocates the core corporate values of "innovation, integrity, cooperation, inclusiveness, and responsibility", and is committed to perseverance, improving the people's healthy quality of life, and striving to build a leading brand drug manufacturer and health service provider that is respected and has an industry reputation.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceutical Group Co., Ltd. is the only pharmaceutical listed company in China that has a leading position in pharmaceutical products and distribution markets. The company's R&D is based on innovation as its long-term adherence to, and is committed to providing safe and effective therapeutic drugs for major diseases and chronic diseases. In 2012, R&D investment accounted for 4.72% of the company's pharmaceutical business sales revenue. The company has established a research and development system for the branch of the Group General Academy with the Central Research Institute as its technical core, with 1 national-level enterprise technology center and 10 provincial and municipal enterprise technology centers, and has been selected for more than ten major national science and technology projects of "major new drug creation". The company adopts an open research model, established a strategic alliance for innovative drug research and development with the Shanghai Institute of Pharmaceuticals of the Chinese Academy of Sciences, established joint laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, etc., and cooperated with Japan's Mitsubishi Tanabe Pharmaceutical Co., Ltd. and Shanghai Fudan Zhangjiang Biomedicine to carry out innovative drug research and development; at the same time, it also began to enter the field of therapeutic antibodies through project introduction, cooperative development and other methods. Shanghai pharmaceutical manufacturing covers the fields of chemical and biological medicine, modern Chinese medicine and health products, medical devices, etc. The products focus on five major therapeutic areas: cardiovascular and cerebrovascular, systemic anti-infection, digestive system and immunometabolism, neuropsychiatric, and anti-tumor. It produces more than 20 dosage forms such as tablets, capsules, powder injections (including lyophilized), small-volume injections, eye drops, aerosols, gels, etc., and has over 100 million products. The company's Xinyi, Leishi, Longhu, Qingchunbao, Hu Qingyutang, Cangsong, Guofeng, Shenxiang and other brands are well-known trademarks in China. The company's pharmaceutical production strictly implements China's new version of GMP requirements, and multiple raw materials or preparations have passed the quality certification of WHO, FDA, the EU and other developed countries. Shanghai Pharmaceutical's distribution network radiates across the country with the three key areas of East China, North China and South China, with the most economically developed in China, and ranks second in the country in terms of business scale. The company's distribution business is mainly hospital pure sales, and it cooperates with more than 40 multinational pharmaceutical companies around the world. The company's new businesses such as vaccines, high-end consumables, DTP (direct delivery of high-value drugs) and SPD (pharmaceutical flow management technology) are leading in China. The company's distribution services are gradually moving towards modern hospital service solutions with supply chain extension services and clinical support services as the core, providing hospital customers with terminal solutions, special logistics and information services. Shanghai Pharmaceutical Retail has many well-known brands such as Fahrenheit, Lei Yunshang, Yu Tiancheng, Life Insurance, Leimon, Keyuan Xinhai Pharmacy, etc., covering 12 provinces, municipalities and autonomous regions across the country, with a total of 1,792 stores. In 2012, the company's pharmaceutical retail sales scale ranked among the top five in the national pharmaceutical retail industry, and Shanghai Fahrenheit Pharmacy is the company with the largest number of pharmacies in East China. Shanghai Pharmaceutical's retail business includes chain pharmacies, co-organized pharmacies, DTP pharmacies and other business formats, and actively develops e-commerce to achieve online sales. Shanghai Pharmaceutical advocates the core corporate values of "innovation, integrity, cooperation, inclusiveness, and responsibility", and is committed to perseverance, improving the people's healthy quality of life, and striving to build a leading brand drug manufacturer and health service provider that is respected and has an industry reputation.
Shandong Bayer Building Materials Co., Ltd.
Bayer Company was founded in 2002 and is located in Pingyi County Industrial Park. It is a collection of gypsum board, soy protein glue, zero-aldehyde and wood board, zero-aldehyde and wood floor, zero-aldehyde and water paint coating. Innovative high-tech enterprises that integrate research and development, production and sales of zero-aldehyde additive product systems and have self-operated import and export rights; they are under the jurisdiction of Shandong Baier Building Materials Co., Ltd., Hunan Baier Gypsum Board Co., Ltd., Shandong Baier New Materials Co., Ltd., Pingyi Baier International Import and Export Co., Ltd., Pingyi Baier Wood Industry Co., Ltd.; has annual production of high-end positioning points paper gypsum board of 120 million square meters, light steel keel 200,000 tons, and soybean protein glue 100,000 tons, The production capacity of zero dehyde added to wooden floors is 500,000 square meters, zero dehyde added to household furnishings, 50,000 tons of water paint coatings, and 15,000 sheets of daily zero dehyde added to wooden boards; the product sales are spread across more than 30 products, including East China, North China, Central China, South China, etc. It is exported to more than 40 countries and regions including North America and the Middle East. Since its establishment, the company has taken "creating a better living environment for mankind" as its ideal, adhered to the concept of "innovative development", and has owned 92 national patents, of which 16 core invention patents have been reached. In 2004, it passed the ISO9001 international quality management system certification; in 2005, it passed the ISO14001 environmental management system certification; in 2008, it passed the ISO10012 metrological testing system certification; in 2017, it won the Linyi Mayor's Quality Nomination Award; in 2018, Passed the US NAF realdehyde-free certification; in 2020, Bayer's top ten zero-aldehyde product systems were put into operation in full, and the company's management and operation capabilities have been continuously improved. Bayer has developed into a well-known enterprise in the building materials industry. The company is the national standards of "Limited Formaldehyde Release in Interior Decoration Materials Artificial Boards and Products", "Paper Dysartboard", "Print Dysartboard Energy Consumption Level Limit"; "Print Dysartboard Unit Yield Energy Consumption Limit", "Connected Paper Belt", "Seaming Gypsum", and "Pattern Gypsum Board Unit Yield Energy Consumption Limit" Industry Standards; it is a Chinese patent Shandong star enterprise, an excellent export foreign exchange enterprise, a Shandong small and medium-sized enterprise innovation and transformation demonstration enterprise, Linyi Municipal entrepreneurial mentor enterprise, provincial enterprise technology research and development center, and national high-tech enterprise; it is the initiator of Shandong Province New Building Decoration and Decoration Materials Industry Technology Innovation Alliance, Shandong Province's "Emergency Needed and Scarce Talents in the Western Economic Uplift Belt" project unit; it was awarded Shandong The first prize of the Provincial Small and Medium-sized Enterprises Science and Technology Progress Award, the "Golden Bridge Award" of the Shandong Provincial Department of Science and Technology and other honorary titles.
Shandong Bayer Building Materials Co., Ltd.
Bayer Company was founded in 2002 and is located in Pingyi County Industrial Park. It is a collection of gypsum board, soy protein glue, zero-aldehyde and wood board, zero-aldehyde and wood floor, zero-aldehyde and water paint coating. Innovative high-tech enterprises that integrate research and development, production and sales of zero-aldehyde additive product systems and have self-operated import and export rights; they are under the jurisdiction of Shandong Baier Building Materials Co., Ltd., Hunan Baier Gypsum Board Co., Ltd., Shandong Baier New Materials Co., Ltd., Pingyi Baier International Import and Export Co., Ltd., Pingyi Baier Wood Industry Co., Ltd.; has annual production of high-end positioning points paper gypsum board of 120 million square meters, light steel keel 200,000 tons, and soybean protein glue 100,000 tons, The production capacity of zero dehyde added to wooden floors is 500,000 square meters, zero dehyde added to household furnishings, 50,000 tons of water paint coatings, and 15,000 sheets of daily zero dehyde added to wooden boards; the product sales are spread across more than 30 products, including East China, North China, Central China, South China, etc. It is exported to more than 40 countries and regions including North America and the Middle East. Since its establishment, the company has taken "creating a better living environment for mankind" as its ideal, adhered to the concept of "innovative development", and has owned 92 national patents, of which 16 core invention patents have been reached. In 2004, it passed the ISO9001 international quality management system certification; in 2005, it passed the ISO14001 environmental management system certification; in 2008, it passed the ISO10012 metrological testing system certification; in 2017, it won the Linyi Mayor's Quality Nomination Award; in 2018, Passed the US NAF realdehyde-free certification; in 2020, Bayer's top ten zero-aldehyde product systems were put into operation in full, and the company's management and operation capabilities have been continuously improved. Bayer has developed into a well-known enterprise in the building materials industry. The company is the national standards of "Limited Formaldehyde Release in Interior Decoration Materials Artificial Boards and Products", "Paper Dysartboard", "Print Dysartboard Energy Consumption Level Limit"; "Print Dysartboard Unit Yield Energy Consumption Limit", "Connected Paper Belt", "Seaming Gypsum", and "Pattern Gypsum Board Unit Yield Energy Consumption Limit" Industry Standards; it is a Chinese patent Shandong star enterprise, an excellent export foreign exchange enterprise, a Shandong small and medium-sized enterprise innovation and transformation demonstration enterprise, Linyi Municipal entrepreneurial mentor enterprise, provincial enterprise technology research and development center, and national high-tech enterprise; it is the initiator of Shandong Province New Building Decoration and Decoration Materials Industry Technology Innovation Alliance, Shandong Province's "Emergency Needed and Scarce Talents in the Western Economic Uplift Belt" project unit; it was awarded Shandong The first prize of the Provincial Small and Medium-sized Enterprises Science and Technology Progress Award, the "Golden Bridge Award" of the Shandong Provincial Department of Science and Technology and other honorary titles.
Merck is a leading pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Merck & Co., Inc.
Merck is a leading pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Eli Lilly is a global pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Eli Lilly and Company
Eli Lilly is a global pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Takeda Pharmaceutical Company Limited
Takeda is a Japanese multinational with a strong portfolio in anti-inflammatory and other therapeutic areas.
Takeda Pharmaceutical Company Limited
Takeda is a Japanese multinational with a strong portfolio in anti-inflammatory and other therapeutic areas.
Bristol-Myers Squibb Company
BMS is a global biopharmaceutical company known for its innovative treatments, including anti-inflammatory drugs.
Bristol-Myers Squibb Company
BMS is a global biopharmaceutical company known for its innovative treatments, including anti-inflammatory drugs.
Gilead focuses on developing and commercializing innovative therapeutics, including anti-inflammatory medications.
Gilead Sciences, Inc.
Gilead focuses on developing and commercializing innovative therapeutics, including anti-inflammatory medications.
A biotechnology pioneer, Amgen develops innovative medicines for serious illnesses, including cancer and cardiovascular diseases.
Amgen Inc.
A biotechnology pioneer, Amgen develops innovative medicines for serious illnesses, including cancer and cardiovascular diseases.
A biotechnology company, Biogen focuses on innovative therapies for neurological and neurodegenerative diseases, such as multiple sclerosis.
Biogen Inc.
A biotechnology company, Biogen focuses on innovative therapies for neurological and neurodegenerative diseases, such as multiple sclerosis.
Known for its innovative medicines in areas like medical aesthetics, eye care, and central nervous system disorders, Allergan is now part of AbbVie.
Allergan plc
Known for its innovative medicines in areas like medical aesthetics, eye care, and central nervous system disorders, Allergan is now part of AbbVie.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
AbbVie Inc.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
AstraZeneca PLC
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
Boehringer Ingelheim (China) Investment Co., Ltd.
Boehringer Ingelheim is committed to researching breakthrough therapies aimed at transforming lives and protecting the health of generations. As a global leading pharmaceutical company driven by R&D, the company demonstrates value through innovation in areas where medical needs are highly unmet. Boehringer Ingelheim has been an independent family business since its establishment in 1885 and has always focused on long-term development. In the three major business areas of human medicine, animal health and biopharmaceutical contract production, more than 52,000 employees worldwide serve more than 130 regions.
Boehringer Ingelheim (China) Investment Co., Ltd.
Boehringer Ingelheim is committed to researching breakthrough therapies aimed at transforming lives and protecting the health of generations. As a global leading pharmaceutical company driven by R&D, the company demonstrates value through innovation in areas where medical needs are highly unmet. Boehringer Ingelheim has been an independent family business since its establishment in 1885 and has always focused on long-term development. In the three major business areas of human medicine, animal health and biopharmaceutical contract production, more than 52,000 employees worldwide serve more than 130 regions.
GlaxoSmithKline (China) Investment Co., Ltd.
GSK is a global biopharmaceutical company with the mission of "growing science, technology and talents, working together to surpass and overcome diseases." Committed to positively impact the health of 2.5 billion people over the next decade. In China, GSK (GSK) is always committed to helping improve the health, life and future of the Chinese people. Vaccines: GSK is a leading vaccine supplier in the Chinese market, committed to improving the accessibility of vaccines to Chinese patients and consumers. Our children and adult vaccines can prevent a variety of diseases: shingles, cervical cancer vaccines, and hepatitis B virus vaccines, including two dosage forms of adults and children. Prescription Drugs: GSK's prescription drug business has a rich innovative and mature product portfolio. In China, it is currently focusing on the following diseases: respiratory system, hepatitis, neurological diseases, HIV/AIDS, as well as immune system diseases including systemic lupus erythematosus and pulmonary hypertension, eosinophilic granulomatous polyangiitis (EGPA) ) Rare diseases.
GlaxoSmithKline (China) Investment Co., Ltd.
GSK is a global biopharmaceutical company with the mission of "growing science, technology and talents, working together to surpass and overcome diseases." Committed to positively impact the health of 2.5 billion people over the next decade. In China, GSK (GSK) is always committed to helping improve the health, life and future of the Chinese people. Vaccines: GSK is a leading vaccine supplier in the Chinese market, committed to improving the accessibility of vaccines to Chinese patients and consumers. Our children and adult vaccines can prevent a variety of diseases: shingles, cervical cancer vaccines, and hepatitis B virus vaccines, including two dosage forms of adults and children. Prescription Drugs: GSK's prescription drug business has a rich innovative and mature product portfolio. In China, it is currently focusing on the following diseases: respiratory system, hepatitis, neurological diseases, HIV/AIDS, as well as immune system diseases including systemic lupus erythematosus and pulmonary hypertension, eosinophilic granulomatous polyangiitis (EGPA) ) Rare diseases.
Beijing Novartis Pharma Ltd.
Novartis ' history can be traced back to three companies that have intersections with it. Gargi established a trading of chemicals and dyes in Basel, Switzerland in the mid-18th century; Ciba began to produce dyes in 1859; Sandoz in 1886 2019 a chemical company was established in Basel. Later, Novartis was formed by the merger of these three companies in 1996. With its predecessor's long and rich experience in developing innovative products, it developed from its initial focus on the production and synthesis of fiber fabric dyes and became a focus on chemistry The world's largest pharmaceutical and health enterprise of product and medicine. Novartis is one of the three largest pharmaceutical companies in the world. Its headquarters is located in Basel, Switzerland. Its business covers more than 150 countries and regions around the world and has 138,000 employees. Novartis is committed to providing innovative medical and healthcare solutions to patients and society to meet their changing health needs, focusing on the four core therapeutic areas where patients need urgently (cardiovascular, kidney and metabolism, tumors, immune, neuroscience) and the five major Technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, gene and cell therapy) continue to develop pioneering therapies. It has a diversified product portfolio, with business departments including innovative drugs (Novartis), ophthalmic health care (Alcon), generic drugs (Sandus), vaccines, and animal health products. The Novartis China headquarters was established in 1997. Its name is "Promise for China", which means improving the health level and quality of life of the Chinese people through continuous innovative products and services. China is one of Novartis' major strategic markets around the world. Novartis has laid out its Chinese market from R&D, production to business development, and has built production bases in Changping, Beijing, and established R&D institutions in Beijing, Shanghai and Jiangsu. Since 1987, Novartis has approved about 100 innovative drugs and new indications in China. In order to accelerate the introduction of innovative drugs, since 2022, Novartis' new drugs and new indications in China have achieved 100% sync with the world; at the same time, Novartis actively promotes the accessibility of innovative drugs, and since 2017, more than 30 have been reported. The drug has been included in the national medical insurance catalog.
Beijing Novartis Pharma Ltd.
Novartis ' history can be traced back to three companies that have intersections with it. Gargi established a trading of chemicals and dyes in Basel, Switzerland in the mid-18th century; Ciba began to produce dyes in 1859; Sandoz in 1886 2019 a chemical company was established in Basel. Later, Novartis was formed by the merger of these three companies in 1996. With its predecessor's long and rich experience in developing innovative products, it developed from its initial focus on the production and synthesis of fiber fabric dyes and became a focus on chemistry The world's largest pharmaceutical and health enterprise of product and medicine. Novartis is one of the three largest pharmaceutical companies in the world. Its headquarters is located in Basel, Switzerland. Its business covers more than 150 countries and regions around the world and has 138,000 employees. Novartis is committed to providing innovative medical and healthcare solutions to patients and society to meet their changing health needs, focusing on the four core therapeutic areas where patients need urgently (cardiovascular, kidney and metabolism, tumors, immune, neuroscience) and the five major Technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, gene and cell therapy) continue to develop pioneering therapies. It has a diversified product portfolio, with business departments including innovative drugs (Novartis), ophthalmic health care (Alcon), generic drugs (Sandus), vaccines, and animal health products. The Novartis China headquarters was established in 1997. Its name is "Promise for China", which means improving the health level and quality of life of the Chinese people through continuous innovative products and services. China is one of Novartis' major strategic markets around the world. Novartis has laid out its Chinese market from R&D, production to business development, and has built production bases in Changping, Beijing, and established R&D institutions in Beijing, Shanghai and Jiangsu. Since 1987, Novartis has approved about 100 innovative drugs and new indications in China. In order to accelerate the introduction of innovative drugs, since 2022, Novartis' new drugs and new indications in China have achieved 100% sync with the world; at the same time, Novartis actively promotes the accessibility of innovative drugs, and since 2017, more than 30 have been reported. The drug has been included in the national medical insurance catalog.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Founded in 1923, Novo Nordisk is a world-leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. The company's goal is to promote change to overcome diabetes and other serious chronic diseases such as obesity, rare blood diseases, endocrine disorders, etc. To achieve this goal, Novo Nordisk leads scientific breakthroughs, expands the company's access to drugs, and is committed to preventing and ultimately curing diseases. Novo Nordisk has about 47,000 employees in 80 countries and regions around the world, providing products and services to more than 168 countries and regions around the world. For nearly 100 years, Novo Nordisk has been committed to addressing unmet medical needs in patients with severe chronic diseases through innovative drugs and drug delivery devices such as insulin pens. Today, Novo Nordisk's treatment options benefit millions of people with diabetes, obesity, rare blood and endocrine diseases. From laboratories to factories, we continue to discover and develop innovative biopharmaceuticals that provide them to patients around the world and improve access to drugs. Novo Nordisk focuses on serious chronic diseases that affect hundreds of millions of people around the world, responding to the world's most urgent health challenges. Novo Nordisk combines innovation with operational excellence capabilities and collaborates with patients and partners to transform bold ideas into drugs that save lives or prevent disease. Novo Nordisk makes long-term investments in innovative treatment options and technologies, including stem cell therapy, to continue to advance the development of medical devices and digital health solutions.
Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Founded in 1923, Novo Nordisk is a world-leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. The company's goal is to promote change to overcome diabetes and other serious chronic diseases such as obesity, rare blood diseases, endocrine disorders, etc. To achieve this goal, Novo Nordisk leads scientific breakthroughs, expands the company's access to drugs, and is committed to preventing and ultimately curing diseases. Novo Nordisk has about 47,000 employees in 80 countries and regions around the world, providing products and services to more than 168 countries and regions around the world. For nearly 100 years, Novo Nordisk has been committed to addressing unmet medical needs in patients with severe chronic diseases through innovative drugs and drug delivery devices such as insulin pens. Today, Novo Nordisk's treatment options benefit millions of people with diabetes, obesity, rare blood and endocrine diseases. From laboratories to factories, we continue to discover and develop innovative biopharmaceuticals that provide them to patients around the world and improve access to drugs. Novo Nordisk focuses on serious chronic diseases that affect hundreds of millions of people around the world, responding to the world's most urgent health challenges. Novo Nordisk combines innovation with operational excellence capabilities and collaborates with patients and partners to transform bold ideas into drugs that save lives or prevent disease. Novo Nordisk makes long-term investments in innovative treatment options and technologies, including stem cell therapy, to continue to advance the development of medical devices and digital health solutions.
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
Roche Holding AG
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
